The U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) number ANDA088292 for imipramine hydrochloride tablets.
The product, marketed under the brand name Imipramine Hydrochloride, is manufactured by Strides Pharma Science Limited. It is an oral prescription tablet available in a 10 mg strength.
The FDA listing includes several National Drug Code (NDC) identifiers—product NDCs 64380-169, 64380-170, and 64380-171—and corresponding package codes such as 64380-169-01, 64380-169-02, 64380-170-01, 64380-170-02, 64380-171-01, and 64380-171-02. The product type is classified as a human prescription drug.
Submission records show multiple manufacturing (CMC) submissions dating from 1983 to 1997 and labeling submissions up to 2005, all with an approved (AP) status.
Actualités réglementaires30 août 2026•1 min de lecture
FDA Approves Imipramine Hydrochloride (ANDA088292)
FDA grants approval for ANDA088292, an oral imipramine hydrochloride tablet by Strides Pharma Science Limited, with details on dosage, NDC codes, and submission history.
Compilé par l'équipe PharmaCountry · Source : FDA.gov
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note